Saturday 17 October 2026
Export SLGL’s income statement to Excel — free account
Sol-Gel Technologies Ltd.
SLGL Healthcare Biotechnology
Sol-Gel Technologies Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $19.4 million, up 68.0% from fiscal 2024. In the quarter to June 2026, revenue fell 96.6%, EPS fell 127.1% and free cash flow fell 8.76%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
64.25
4.45
−6.48%
Follow SLGL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
135.10 | 12.17 | 6.06 | 4.28 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(29.34) | 697.97 | 364.60 | 135.58 | |
P/B ratio |
5.04 | 4.37 | 5.15 | 3.12 | |
Price to Tangible BV |
5.04 | 4.37 | 5.15 | 3.12 | |
EV/Sales |
144.80 | 12.85 | 8.19 | 6.63 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(12.24) | (11.52) | (7.71) | (4.30) | |
EV/FCF |
(12.22) | (11.51) | (7.70) | (4.29) | |
Quick Ratio |
9.87 | 8.54 | 4.21 | 4.99 | |
Current Ratio |
10.37 | 8.84 | 4.37 | 5.15 | |
Net Debt/EBITDA |
11.52 | 13.70 | 7.04 | 3.31 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.04 | 0.43 | 0.59 | 0.49 | |
Operating CF/Net income |
2.25 | 0.00 | (0.11) | 0.00 | |
Capex/Depreciation |
(0.67) | — | 0.06 | — | |
Research and Development Expense of Revenue |
629.27% | 2,579.63% | 514.94% | 1,432.75% | |
Selling, General and Administrative Expense of Revenue |
174.96% | 1,089.81% | 82.90% | 239.25% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.19 | 0.22 | 0.17 | 0.28 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.61%) | (0.43%) | (5.29%) | (11.18%) | |
Free Cash Flow Yield |
(8.77%) | (9.17%) | (17.55%) | (36.06%) | |
Revenue per Share |
0.18 | 0.04 | 0.25 | 0.14 | |
Operating CF per Share |
(2.53) | 0.00 | 0.12 | 0.00 | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.53) | 0.00 | 0.12 | 0.00 | |
Cash per Share |
14.65 | 18.62 | 8.61 | 7.48 | |
Shareholders Equity per Share |
14.70 | 18.12 | 8.19 | 9.34 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
14.70 | 18.12 | 8.19 | 9.34 | |
Free Cash Flow |
(8.29) | — | 0.33 | — | |
Working Capital |
46.15 | 49.48 | 20.80 | 25.51 | |
Capital Expenditures |
(0.03) | — | 0.01 | — | |
Net Current Asset Value |
45.42 | 48.65 | 19.87 | 23.09 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.00 | (0.01) | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.38 | 2.48 | 2.78 | 8.43 | |
Average Payables |
1.04 | 0.61 | 1.00 | 1.17 | |
Average Assets |
46.53 | 42.81 | 32.88 | 38.79 | |
Average Common Equity |
39.99 | 35.79 | 25.83 | 30.37 |
Columns are period end dates